Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Keith Bass

Nurse Practitioner, Family Anna, IL Nurse Practitioner

NPI 1114440179 CMS profile 10874512

513 N Main St, Anna, IL 62906

Open in the dashboard

General payments

$31,054

287 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Keith Bass of Anna, IL is reported in the CMS Open Payments database as having received $31,054 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,849 107
2024 General $18,740 79
2023 General $472 35
2022 General $527 36
2021 General $465 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Bass
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Keith Bass were reported at $10,849. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Keith Bass Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $465 $124 $35–$379 $132
2022 $527 $141 $44–$430 $149
2023 $472 $154 $49–$476 $160
2024 $18,740 $165 $51–$504 $164
2025 $10,849 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $29,636 196 payments
  2. Alkermes, Inc. $411 46 payments
  3. Janssen Pharmaceuticals, Inc $305 9 payments
  4. ITI, Inc. $279 15 payments
  5. Axsome Therapeutics, Inc. $156 3 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $78 5 payments
  7. Otsuka America Pharmaceutical, Inc. $58 4 payments
  8. Sunovion Pharmaceuticals Inc. $53 4 payments
  9. Supernus Pharmaceuticals, Inc. $33 2 payments
  10. Uswm, LLC $31 2 payments
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25,738 25 payments
  2. Food and Beverage $3,742 243 payments
  3. Travel and Lodging $1,575 19 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $19,526 146 payments
  2. VRAYLAR Neuroscience $10,110 50 payments
  3. LYBALVI $411 46 payments
  4. ARISTADA Cns $411 46 payments
  5. ARISTADA Cns $411 46 payments
  6. ARISTADA Cns $361 43 payments
  7. ARISTADA Cns $361 43 payments
  8. SPRAVATO $305 9 payments
  9. CAPLYTA $250 13 payments
  10. Auvelity $156 3 payments
  11. Other $428 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

7,337

Median for Nurse Practitioner: 389

Drug cost

$1,132,590

Median for Nurse Practitioner: $21,885

Branded share of claims

19%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 342 $521,900
Invega Sustenna Paliperidone Palmitate Brand 62 $175,973
Austedo Deutetrabenazine Brand 19 $98,128
Rexulti Brexpiprazole Brand 68 $75,744
Lybalvi Olanzapine/Samidorphan Malate Brand 29 $47,887
Trintellix Vortioxetine Hydrobromide Brand 60 $31,155
Auvelity Dextromethorphan Hbr/Bupropion Brand 14 $19,378
Aripiprazole Generic 322 $14,828
Paliperidone Er Paliperidone Brand 61 $11,256
Chlorpromazine Hcl Generic 23 $10,225

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $18,396
$18,396 342 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $285
$285 — —
ARISTADA
  • Alkermes, Inc. $22
$22 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $17
$17 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $14
$14 68 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record